DEM BioPharma is an immuno-oncology company dedicated to eradicating cancer by targeting novel innate immune system checkpoints. The company focuses on unleashing the power of macrophages and other myeloid effector cells to eliminate tumors. Utilizing their proprietary CHoMP™ platform, DEM BioPharma systematically identifies unexplored 'don’t eat me' (DEM) and 'eat me' (EM) signals on cancer cells and macrophages, aiming to develop next-generation immunotherapeutics.
DEM BioPharma has made significant strides in the field of immuno-oncology by pioneering innovative approaches to cancer treatment. Their CHoMP™ platform represents a key technological advancement in identifying new therapeutic targets, contributing to the development of more effective cancer therapies. The company's impact is marked by its commitment to leveraging the innate immune system's potential to combat cancer, positioning itself as a leader in the next wave of immunotherapeutic innovation.
